Human endogenous retrovirus K in the respiratory tract is associated with COVID-19 physiopathology.
Journal
Microbiome
ISSN: 2049-2618
Titre abrégé: Microbiome
Pays: England
ID NLM: 101615147
Informations de publication
Date de publication:
22 04 2022
22 04 2022
Historique:
received:
04
10
2021
accepted:
15
03
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
27
4
2022
Statut:
epublish
Résumé
Critically ill 2019 coronavirus disease (COVID-19) patients under invasive mechanical ventilation (IMV) are 10 to 40 times more likely to die than the general population. Although progression from mild to severe COVID-19 has been associated with hypoxia, uncontrolled inflammation, and coagulopathy, the mechanisms involved in the progression to severity are poorly understood. The virome of tracheal aspirates (TA) from 25 COVID-19 patients under IMV was assessed through unbiased RNA sequencing (RNA-seq), and correlation analyses were conducted using available clinical data. Unbiased sequences from nasopharyngeal swabs (NS) from mild cases and TA from non-COVID patients were included in our study for further comparisons. We found higher levels and differential expression of human endogenous retrovirus K (HERV-K) genes in TA from critically ill and deceased patients when comparing nasopharyngeal swabs from mild cases to TA from non-COVID patients. In critically ill patients, higher HERV-K levels were associated with early mortality (within 14 days of diagnosis) in the intensive care unit. Increased HERV-K expression in deceased patients was associated with IL-17-related inflammation, monocyte activation, and an increased consumption of clotting/fibrinolysis factors. Moreover, increased HERV-K expression was detected in human primary monocytes from healthy donors after experimental SARS-CoV-2 infection in vitro. Our data implicate the levels of HERV-K transcripts in the physiopathology of COVID-19 in the respiratory tract of patients under invasive mechanical ventilation. Video abstract.
Sections du résumé
BACKGROUND
Critically ill 2019 coronavirus disease (COVID-19) patients under invasive mechanical ventilation (IMV) are 10 to 40 times more likely to die than the general population. Although progression from mild to severe COVID-19 has been associated with hypoxia, uncontrolled inflammation, and coagulopathy, the mechanisms involved in the progression to severity are poorly understood.
METHODS
The virome of tracheal aspirates (TA) from 25 COVID-19 patients under IMV was assessed through unbiased RNA sequencing (RNA-seq), and correlation analyses were conducted using available clinical data. Unbiased sequences from nasopharyngeal swabs (NS) from mild cases and TA from non-COVID patients were included in our study for further comparisons.
RESULTS
We found higher levels and differential expression of human endogenous retrovirus K (HERV-K) genes in TA from critically ill and deceased patients when comparing nasopharyngeal swabs from mild cases to TA from non-COVID patients. In critically ill patients, higher HERV-K levels were associated with early mortality (within 14 days of diagnosis) in the intensive care unit. Increased HERV-K expression in deceased patients was associated with IL-17-related inflammation, monocyte activation, and an increased consumption of clotting/fibrinolysis factors. Moreover, increased HERV-K expression was detected in human primary monocytes from healthy donors after experimental SARS-CoV-2 infection in vitro.
CONCLUSION
Our data implicate the levels of HERV-K transcripts in the physiopathology of COVID-19 in the respiratory tract of patients under invasive mechanical ventilation. Video abstract.
Identifiants
pubmed: 35459226
doi: 10.1186/s40168-022-01260-9
pii: 10.1186/s40168-022-01260-9
pmc: PMC9024070
doi:
Types de publication
Journal Article
Video-Audio Media
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
65Informations de copyright
© 2022. The Author(s).
Références
Am J Emerg Med. 2020 Sep;38(9):1722-1726
pubmed: 32738466
Anesth Analg. 2020 Oct;131(4):993-999
pubmed: 32925314
J Exp Med. 2021 Mar 1;218(3):
pubmed: 33231615
Bioinformatics. 2012 Apr 15;28(8):1166-7
pubmed: 22368248
Front Immunol. 2020 Oct 23;11:580250
pubmed: 33178207
Ann Hematol. 2020 Jul;99(7):1421-1428
pubmed: 32495027
Clin Cancer Res. 2013 Nov 15;19(22):6112-25
pubmed: 24081977
Proc Natl Acad Sci U S A. 2021 May 25;118(21):
pubmed: 33958444
Mol Biol Evol. 2018 Jun 1;35(6):1547-1549
pubmed: 29722887
J Emerg Dis Virol. 2017 Aug;3(2):
pubmed: 28868516
Int J Infect Dis. 2021 Feb;103:25-32
pubmed: 33186704
Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):495-502
pubmed: 33389263
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9879-84
pubmed: 23716685
Nat Rev Immunol. 2021 May;21(5):319-329
pubmed: 33824483
J Antimicrob Chemother. 2021 Jun 18;76(7):1874-1885
pubmed: 33880524
BMC Biochem. 2011 May 05;12:18
pubmed: 21545744
J Virol. 2017 Nov 14;91(23):
pubmed: 28931682
Nat Microbiol. 2021 Jan;6(1):73-86
pubmed: 33340034
Blood. 2008 Feb 1;111(3):1182-92
pubmed: 17975014
J Infect Dis. 2014 May 1;209(9):1331-42
pubmed: 24065148
Am J Respir Crit Care Med. 2021 Jan 15;203(2):192-201
pubmed: 33217246
EBioMedicine. 2021 Apr;66:103341
pubmed: 33867312
Am J Respir Crit Care Med. 2021 Jan 1;203(1):54-66
pubmed: 33119402
Retrovirology. 2020 May 6;17(1):10
pubmed: 32375827
J Exp Med. 2005 Aug 1;202(3):415-24
pubmed: 16043521
Am J Hematol. 2020 Jul;95(7):834-847
pubmed: 32282949
PLoS One. 2014 Jul 02;9(7):e97984
pubmed: 24988390
Nucleic Acids Res. 2020 Jan 8;48(D1):D328-D334
pubmed: 31724716
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
J Exp Med. 2020 Dec 7;217(12):
pubmed: 32926098
Microb Pathog. 2018 Feb;115:189-193
pubmed: 29274460
Front Pharmacol. 2020 Oct 09;11:572009
pubmed: 33162887
J Gen Virol. 2016 Feb;97(2):344-355
pubmed: 26602089
Arch Virol. 2017 Dec;162(12):3639-3644
pubmed: 28821995
Front Cell Infect Microbiol. 2021 Feb 25;11:609160
pubmed: 33732659
Cell Commun Signal. 2019 Aug 14;17(1):94
pubmed: 31412880
Trends Immunol. 2017 May;38(5):310-322
pubmed: 28254169
Nat Protoc. 2016 Jan;11(1):102-17
pubmed: 26658470
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Hum Genomics. 2021 Jan 4;15(1):2
pubmed: 33390179
Front Pediatr. 2020 May 14;8:244
pubmed: 32478020
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Bioinformatics. 2019 Mar 1;35(5):871-873
pubmed: 30124794
Circulation. 2017 Nov 14;136(20):1920-1935
pubmed: 28935667
Front Microbiol. 2018 Mar 14;9:462
pubmed: 29593697
Nat Med. 2020 Oct;26(10):1623-1635
pubmed: 32807934
Nat Rev Rheumatol. 2010 Apr;6(4):232-41
pubmed: 20177398
Life Sci. 2020 Sep 15;257:118102
pubmed: 32687918
Retrovirology. 2011 Nov 08;8:90
pubmed: 22067224
J Infect Dis. 2021 Mar 3;223(5):785-795
pubmed: 33277988
Front Microbiol. 2020 Jul 17;11:1690
pubmed: 32765477
Lancet Microbe. 2020 Nov;1(7):e290-e299
pubmed: 33015653
Cell. 2020 Sep 17;182(6):1419-1440.e23
pubmed: 32810438
Sci Rep. 2021 Oct 12;11(1):20254
pubmed: 34642411
PLoS Pathog. 2020 Dec 16;16(12):e1009127
pubmed: 33326472
Nucleic Acids Res. 2021 Jan 8;49(D1):D480-D489
pubmed: 33237286
PLoS One. 2013 Aug 07;8(8):e70399
pubmed: 23950929
Front Immunol. 2021 Jul 21;12:720109
pubmed: 34367190
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409
pubmed: 32270184
Curr Probl Cardiol. 2021 Mar;46(3):100742
pubmed: 33243440
J Infect Dis. 2021 Aug 2;224(3):395-406
pubmed: 33493287
Cytometry A. 2020 Sep;97(9):887-890
pubmed: 32654350
EClinicalMedicine. 2021 Aug;38:100993
pubmed: 34222849
Cell Death Discov. 2021 Mar 1;7(1):43
pubmed: 33649297
Antimicrob Agents Chemother. 2020 Sep 21;64(10):
pubmed: 32759267
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677
Microbiol Spectr. 2021 Oct 31;9(2):e0126021
pubmed: 34612698
Lancet. 2003 May 24;361(9371):1773-8
pubmed: 12781536
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
PLoS Pathog. 2017 Jun 26;13(6):e1006451
pubmed: 28651004
Lancet Microbe. 2020 May;1(1):e14-e23
pubmed: 32835326